A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients

Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie
Gianluca ManniM G Bucci

Abstract

New effective hypotensive agents have been recently introduced into clinical practice, but often more than one drug has to be used to prevent further visual field loss. The aim of this study was to evaluate the intraocular pressure (IOP)-lowering efficacy and safety of bimatoprost 0.03% compared with the association of timolol 0.5% and latanoprost 0.005% in open-angle glaucoma patients. In this 6-month, prospective, parallel, randomised, investigator-masked clinical trial, 61 glaucomatous patients treated with timolol 0.5% twice in both eyes were enrolled. The timolol 0.5% was replaced by bimatoprost 0.03% once daily (group I) or by latanoprost 0.005% plus timolol 0.5% (group II). IOP measurements were performed at the baseline visit and at days 15, 30, 60, 90, 120 and 180. Digital colour photography was used to evaluate topical side effects. Fifty-six of the 61 patients were included for the intent-to-treat analysis (28 in group I and 28 in group II). Baseline mean IOP was similar in the two groups (p=0.5). Both treatments lowered the mean IOP at every visit significantly compared with the baseline (p<0.01). Comparing the IOP reductions obtained by the two treatments, no significant differences were found at any time during th...Continue Reading

References

Sep 1, 1992·International Ophthalmology·M BatterburyD Wong
Feb 13, 2001·American Journal of Ophthalmology·R F BrubakerA M Vandenburgh
Jun 13, 2001·Acta Ophthalmologica Scandinavica·A M BronM Johansson
Jul 4, 2001·Survey of Ophthalmology·R F Brubaker
Sep 27, 2001·Advances in Therapy·S GandolfiUNKNOWN Bimatoprost Study Group 3
Dec 13, 2001·European Journal of Pharmacology·N A SharifC R Kelly
Mar 27, 2002·The British Journal of Ophthalmology·P J PisellaC Baudouin
Apr 3, 2002·Ophthalmology·Carl B Camras
May 31, 2002·American Journal of Ophthalmology·Daniel J O'ConnorAlden Mead
Sep 3, 2002·Survey of Ophthalmology·Joern B Soltau, Thom J Zimmerman
Oct 9, 2002·Archives of Ophthalmology·Anders HeijlUNKNOWN Early Manifest Glaucoma Trial Group
Oct 9, 2002·Archives of Ophthalmology·Eve J HigginbothamUNKNOWN Bimatoprost Study Groups 1 and 2
Oct 9, 2002·Archives of Ophthalmology·Paul R Lichter
Nov 9, 2002·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Masahiko SugimotoYukitaka Uji
Nov 14, 2002·American Journal of Ophthalmology·Paul J Lama

❮ Previous
Next ❯

Citations

Nov 26, 2005·Current Medical Research and Opinion·Stefan HolmstromMark Aagren
Dec 18, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·D M HutchisonN A Mesinkovska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Thom J ZimmermanLatanoprost Axis Study Group
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Thomas K MundorfWilliam C Stewart
© 2022 Meta ULC. All rights reserved